Drug ID:Drug24
Drug Name:Losartan
CID:3961
DrugBank ID:DB00678
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT02760615
Molecular Formula:C22H23ClN6O
Molecular Weight:422.9 g/mol
Isomeric SMILES:CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Synonyms:losartan; 114798-26-4; DUP 89; Angizaar; Losartic; Lozap; CHEBI:6541; DUP-89; DTXSID7023227; UNII-JMS50MPO89
Phase 0: 17
Phase 1: 79
Phase 2: 80
Phase 3: 102
Phase 4: 122
Description:Losartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt219 3961 Losartan 21 ABCA3 Homo sapiens (human) Agonist
dt220 3961 Losartan 312 ANXA13 Homo sapiens (human) Agonist
dt221 3961 Losartan 272 AMPD3 Homo sapiens (human) Inhibitor
dt222 3961 Losartan 185 AGTR1 Homo sapiens (human) Antagonist
dt223 3961 Losartan 19 ABCA1 Homo sapiens (human) Agonist
dt224 3961 Losartan 18 ABAT Homo sapiens (human) Agonist
dt225 3961 Losartan 2057 EPOR Homo sapiens (human) 37713619 Stimulator
dt226 3961 Losartan 1559 CYP2C9 Homo sapiens (human) Substrate
dt227 3961 Losartan 1576 CYP3A4 Homo sapiens (human) Substrate|Inhibitor

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT02760615 Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study PHASE4 WITHDRAWN Takeda Colitis, Ulcerative|Crohn Disease DRUG: Caffeine|DRUG: Losartan|DRUG: Omeprazole|DR… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

The angiotensin receptor blocker, losartan, reduces inflammation and fibrosis, …

PMID: 40390697
Year: 2025
Relationship Type: Treatment Score: 6.5

BACKGROUND AND AIMS: The renin-angiotensin system (RAS) is known to modulate fibrosis, which is a common complication of ileal Crohn's disease. We te…

View Details
AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mous…

PMID: 26676112
Year: 2016
Relationship Type: Association Score: 6.3

Angiotensin II, which is the main effector of the renin‑angiotensin system, has an important role in intestinal inflammation via the angiotensin II t…

View Details